Robert Hofmeister, PhD

Robert New.jpg

Dr. Hofmeister joined TCR² in 2015 as the Senior Vice President of Research and Development. He brings nearly two decades of scientific leadership and a successful track record of drug discovery and early development. Previously, Dr. Hofmeister was the Vice President of Immuno-Oncology at EMD Serono where he was involved in the development of now approved Bavencio® (avelumab) and building the company’s immuno-oncology platform. He started his biotech career at Micromet AG, now Amgen Research Munich, where he helped shape the development of Blincyto®, the first FDA-approved bispecific antibody for the treatment of relapsed/refractory ALL. Dr. Hofmeister received his PhD from the University of Regensburg in Germany, where he studied the signaling of the cytokine interleukin-1. He continued to work in the cytokine field as a postdoctoral fellow at the National Cancer Institute.